Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

Taylor HS, Giudice Lc, Lessey BA, Abrão Ms, Jan Kotarski, Archer Df, Michael P. Diamond, ES Surrey, Johnson Np, Watts Nb, Gallagher Jc, Simon Ja, Carr BR, W. Paul Dmowski, Nicholas Leyland, Rowan JP, Duan WR, Joseph Ng, Brittany Schwefel, Thomas Jw, Jain RI, Kristof Chwalisż
In: Yearbook of Paediatric Endocrinology · 2018 · doi:10.1530/ey.15.15.6 · W2944549508
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This study investigated elagolix, an oral GnRH antagonist, for endometriosis-associated pain, demonstrating its rapid reduction of gonadotropin and estradiol levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the clear findings here confirm the pathogenesis of endometriosis as being driven by an over-active hypothalamo-pituitary-ovarian axis, and support the rationale for other therapeutic options to reduce ovulation and suppress circulating estradiol levels. Thirdly, could there be other childhood indications for an oral GnRH antagonist treatment? Unlike our traditional therapy, GnRH analogues, which cause profound depletion of pituitary gonadotrophins and estradiol levels after an initial surge, this GnRH antagonist rapidly reduces gonadotrophin and estradiol levels, particularly at the higher dose. Treatments for precocious puberty or to extend the duration of puberty and associated adolescent growing window might be possible uses to test in future trials.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Cited by (7)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK